期刊文献+

靶向联合阻断表皮生长因子受体和环氧化酶-2信号通路影响鼻咽癌细胞生长的研究 被引量:4

The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell
原文传递
导出
摘要 目的:观察联合阻断表皮生长因子受体(EGFR)和环氧化酶-2(COX-2)介导的信号通路,对鼻咽癌细胞株CNE-2的影响。方法:用EGFR-酪氨酸激酶拮抗剂和COX-2抑制剂单独和联合处理鼻咽癌细胞株CNE-2,采用CCK-8法检测细胞生长抑制率,流式细胞术进行细胞周期、凋亡率的分析,Westernblot检测相关蛋白表达。结果:①联合用药组CNE-2细胞生长抑制率显著大于两者单独处理组生长抑制率之和(P<0.05);②联合处理组细胞G1期比例大于单独处理组(P<0.05)。联合处理组细胞凋亡率与单独处理组相比差异无统计学意义(P>0.05);③与单独处理组相比,联合处理组出现明显的p-EGFR,COX-2表达下调。结论:联合阻断EGFR和COX-2信号通路对抑制鼻咽癌细胞株CNE-2生长,增加G1期阻滞及抑制EGFR的磷酸化和COX-2的表达方面具有协同作用。 Objective:This study was designed to prove simultaneously blocking both EGFR and COX-2-mediated pathways may be an efficient means of inhibiting cancer cell growth in NPC. Method: A combination of tarceva (EGFR-selectivetyrosine kinase inhibitors) with celecoxib (Cox-2 inhibitor) was studied on its effects on cell growth, cell cycle progression, apoptosis and protein expression in CNE-2 cell lines by cell growth assay, flow cytometric analysis assay and Western blotting. Resuit:①The inhibition rate of cell growth was higher in the group treated with a combination of two agents than that the sum of rates of the two groups treated with only one agent (P〈0.05). ②The combination of tarceva with celecoxib significantly induced G1 arrest(P〈0.05), but did not increase apoptosis rate(P〉0. 05). ③The group of combination showed less expressions of p-EGFR and COX-2 than any other group. Conclusion: Simultaneously blocking EGFR and COX-2 mediated pathways would significantly inhibit the growth of CNE-2 cell line, increase G1 arrest and reduce the expression levels of p-EGFR and COX-2.
出处 《临床耳鼻咽喉头颈外科杂志》 CAS CSCD 北大核心 2009年第18期817-820,823,共5页 Journal of Clinical Otorhinolaryngology Head And Neck Surgery
基金 湖南省科技厅重点项目(No:07SK2003) 湖南省科技厅项目(No:2007SK3050) 湖南省自然科学基金(No:08JJ5017)
关键词 鼻咽肿瘤 表皮生长因子受体 环氧化酶-2 联合靶向治疗 nasopharyngeal neoplasms epidermal growth factor receptor cyclooxygenase-2 combined targeting therapy
  • 相关文献

参考文献16

  • 1储大同.肿瘤分子靶向治疗的现状及进展[J].中国实用内科杂志,2005,25(8):673-675. 被引量:10
  • 2TORRANCE C J, JACKSON P E, MONTGOMERY E,et al. Combinational chemoprevention of intestinal neoplasia[J]. Nat Med,2000, 61 1024-1028.
  • 3CHUA D T, NICHOLLS J M, SHAM J S, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopha- ryngeal carcinoma treated with induction chemotherapy and radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004,59,11-20.
  • 4THORNBURG N J, RAAB-TRAUB N. Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal- activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes[J]. J Virol, 2007, 81 12954-12961.
  • 5SOULIERES D, SENZER N N, VOKES E E, et al. Multicenter phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck[J]. J Clin Oncol, 2004, 22:77- 85.
  • 6蒋代华,郭德玉,李皓谆,邓蔚.塞来昔布抑制人鼻咽癌细胞株HNE-1细胞增殖与血管内皮生长因子的表达[J].中华耳鼻咽喉头颈外科杂志,2006,41(11):809-812. 被引量:4
  • 7DANNENBERG A J, SUBBARAMAIAH K. Targetingcyclooxygenase 2 in human neoplasia: rationale and promise[J]. Cancer Cell, 2003,4 : 431 - 436.
  • 8BACKLUND M G, MANN J R, HOLLA V R,et al. 15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer[J]. J Biol Chem, 2005,280: 3217-3223.
  • 9SHAO J, LEE S B, GUO H, et al. ProstaglandinE2 stimulates the growth of colon cancer cells via induction of amphiregulin[J]. Cancer Res,2003,63:5218 -23.
  • 10PAl R, SOREGHAN B, SZABO I L, et al. Prostaglandin E2 transactivates EGF receptor: a novelmechanismfor promotingcolon cancer growth and gastrointestinal hypertrophy[J]. Nat Med, 2002,8 : 289- 93.

二级参考文献24

  • 1Half E, Broaddus R, Danenberg KD, et al. HER - 2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer, 2004, 108:540-548.
  • 2Sekharam M, Zhao H, Sun M, et al. Insulin - like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt//3cl - x (L) pathway. Cancer Res, 2003, 63:7708-7716.
  • 3Chun Y J, Park S, Yang SA, et al. Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells. Toxicol Lett, 2003, 146:75-81.
  • 4Ohana G, Bar Yehuda S, Arich A, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer, 2003, 89: 1552- 1558.
  • 5FIainsworth JD, Sosrnan JA, Spigel DR, et al. Phase Ⅱ trial ofbevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Proc Am Soc Clin Oncol, 2004, 22: 382s (abstr 4502).
  • 6Motzer RJ, Rini BI, Michaelson MD, et al. SUO 11248, a novel tyrosine kinase inhibitor, shows antitumor activity in secondline therapy for patients with metastatic renal cell carcinoma:results of a phase 2 trial. Proc Am Soc Clin Oncol, 2004, 22 :382s (abstr 4500).
  • 7Drach J, Kaufmarm H, Woehrer S, et al. Durable remissions after rituximab plus tha. lidomide for relapsed/refractory mantle cell lymphoma. Proc Am Soc Clin Oncol, 2004, 22: 578s (abstr 6583).
  • 8Dannenberg AJ, Ahorki NK, Boyle JO, et al. Cyclo-oxygenase 2 : a pharmacological target for the prevention of cancer. Lancet Oncol,2001, 2: 544-551.
  • 9Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mananary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prey, 2003, 12 : 1486-1491.
  • 10Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol, 2004, 171: 59-63.

共引文献12

同被引文献58

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部